Insider Sale and Recent Performance of Kestra Medical Technologies Ltd

Brian Daniel Webster, President and Chief Executive Officer (and director) of Kestra Medical Technologies Ltd (ticker KMTS), disposed of a total of $692,214 worth of common shares in three separate, nondiscretionary transactions conducted between July 30 and August 3 2026. The sales were executed to satisfy tax‑withholding obligations arising from the vesting and settlement of restricted stock units.

  • On July 30, Webster sold 7,857 shares at a weighted‑average price of $22.7225 per share, with individual transaction prices ranging from $22.2524 to $23.1700.
  • On July 31, he sold an additional 8,948 shares at a weighted‑average price of $22.6039 per share, with individual prices between $22.0577 and $22.9200.
  • On August 3, the final transaction involved 13,017 shares sold at a weighted‑average price of $23.9244 per share, with individual prices ranging from $23.6400 to $24.1100.

The three transactions represent a total of 29,822 shares sold. Following these disposals, Webster beneficially owns 527,115 KMTS common shares.

At the time of reporting, KMTS stock was trading at $28.02 per share, close to its 52‑week high of $30.00 and reflecting a 75 % gain over the prior twelve months. InvestingPro’s analysis flagged the stock as appearing overvalued relative to its fair‑value estimate, placing it on the platform’s “Most Overvalued” watch list.

In parallel, Kestra Medical disclosed its fiscal fourth‑quarter 2026 results. Revenue climbed to $28.6 million, a 66 % year‑over‑year increase and surpassing the consensus estimate of $26.5 million. However, the company posted a loss per share of $0.67, missing the Wall Street forecast of a $0.58 loss per share.

Analyst reactions were broadly positive on the revenue momentum: Stifel reiterated its Buy rating with a price target of $30.00; Wolfe Research raised its target to $30.00 from $29.00; JPMorgan initiated coverage with an Overweight rating and a $30.00 price target, highlighting the potential of the ASSURE wearable cardioverter‑defibrillator; and Oppenheimer began coverage with a Perform rating, citing a large addressable market and ongoing market‑share gains against incumbents.

---